{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Lorenzen S"],"pubmed_abstract":["This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX + nivolumab 240 mg every two weeks + ipilimumab 1 mg/kg every six weeks in parallel or Arm B (mFOLFOX). Subsequently, patients are randomized 1:2 to Arm A1 (identical to Arm A) or Arm A2 (three cycles of mFOLFOX followed by nivolumab + ipilimumab). In Arm C all patients receive FLOT + nivolumab. Primary endpoint is progression-free survival. Secondary endpoints include overall survival and objective response rate. Median progression-free survival (months) is: Arm A/A1, 5.8"],"journal":["Nature communications"],"pagination":["2072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948978"],"repository":["biostudies-literature"],"pubmed_title":["First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial."],"pmcid":["PMC12948978"],"pubmed_authors":["Angermeier S","Luley KB","Pink D","Thuss-Patience PC","Junge S","Goekkurt E","Hofheinz RD","Schuch G","Lindig U","Lorenzen S","Folprecht G","Goetze TO","Riera-Knorrenschild J","Bitzer M","Heinemann V","Bolling C","Ettrich TJ","Pauligk C","Dechow TN","Al-Batran SE","Loose M"],"additional_accession":[]},"is_claimable":false,"name":"First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.","description":"This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX + nivolumab 240 mg every two weeks + ipilimumab 1 mg/kg every six weeks in parallel or Arm B (mFOLFOX). Subsequently, patients are randomized 1:2 to Arm A1 (identical to Arm A) or Arm A2 (three cycles of mFOLFOX followed by nivolumab + ipilimumab). In Arm C all patients receive FLOT + nivolumab. Primary endpoint is progression-free survival. Secondary endpoints include overall survival and objective response rate. Median progression-free survival (months) is: Arm A/A1, 5.8","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T23:26:23.362Z","creation":"2026-07-12T03:11:28.987Z"},"accession":"S-EPMC12948978","cross_references":{"pubmed":["41760643"],"doi":["10.1038/s41467-026-69622-7"]}}